Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Yahoo
Alkermes reported positive Phase 1 results for ALKS 7290, an experimental orexin 2 receptor agonist for ADHD, showing significant reductions in ADHD symptoms and improved disease severity. The drug was well tolerated, with no serious adverse events, and demonstrated early improvements in attention and cognitive function. The findings suggest a new treatment approach targeting brain pathways involved in wakefulness and cognition.
All articles from 24 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.